The current medications for HCV are ribavirin and Pegylated- Interferon. Protease inhibitors are emerging. Accurately predicting the patients who will respond to therapy is becoming important, for patient care and also with respect to the cost. Studies have shown that IL28B are strongly associated with the response to treatment of hepatitis C. We proved in our study on 200 patients that IL28B is the strongest predictor of response of treatment by Peg/ ribavirin and CC allele has the best chance to respond to treatment. Also, BMI, ALT and ALP could be used as predictors for response.